Hafnarfirði, Iceland, Oct 23, 2007 - (Hugin via Asia Business News) - - Actavis product already on market in 6 other countries including Germany and the US
Reykjavik, Iceland, 23 October 2007 -- Actavis Group, the international generic pharmaceuticals company, today announced that it has launched Fentanyl patch for severe chronic pain in Finland, Sweden and Poland. The Actavis Fentanyl patch was launched earlier this year into Actavis' markets in six other countries, including Germany and the United States, with more market launches to follow.
Fentanyl transdermal patch is indicated for the management of persistent, moderate to severe chronic pain that requires continuous, around the clock opioid administration for an extended period of time and cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate release opioids.
Fentanyl transdermal patch is the generic equivalent of Alza Janssen's Duragesic®. The patches deliver consistent and reliable pain relief for 72 hours. They are discreet, easy to use, and are available in up to five strengths to suit the needs of the individual; 12, 25, 50, 75, and 100 micrograms per hour.
Annual global sales of Fentanyl transdermal patches in the European Economic Area were approximately EUR 657 million for the twelve months ending March 2007, according to IMS Health data.
About Actavis Group Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. Based in Iceland, the company has operations in about 40 countries, with more than 11,000 employees. Actavis expects 2007 sales to total EUR1.6bn, with approximately one-third of these sales coming from the United States, the company's single largest market.
Enquiries Actavis Group Hjördís Árnadóttir Director External Communications Tel: (+354) 535 2300 / 840 7476 E-mail: harnadottir@actavis.com
Any statements contained in this news release that refer to Actavis' estimated or anticipated future results or future activities are forward-looking statements which reflect the Company's current analysis of existing trends, information and plans. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially depending on factors such as the availability of resources, the timing and effect of regulatory actions, the success of new products, the strength of competition, the success of research and development issues, unexpected contract breaches or terminations, exposure to product liability and other lawsuits, the effect of currency fluctuations and other factors.
Copyright © Hugin ASA 2007. All rights reserved.
Actavis
http://www.actavis.com
ISIN: IS0000000420
Stock Identifier: ICEX.ACT
Reykjavik, Iceland, 23 October 2007 -- Actavis Group, the international generic pharmaceuticals company, today announced that it has launched Fentanyl patch for severe chronic pain in Finland, Sweden and Poland. The Actavis Fentanyl patch was launched earlier this year into Actavis' markets in six other countries, including Germany and the United States, with more market launches to follow.
Fentanyl transdermal patch is indicated for the management of persistent, moderate to severe chronic pain that requires continuous, around the clock opioid administration for an extended period of time and cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate release opioids.
Fentanyl transdermal patch is the generic equivalent of Alza Janssen's Duragesic®. The patches deliver consistent and reliable pain relief for 72 hours. They are discreet, easy to use, and are available in up to five strengths to suit the needs of the individual; 12, 25, 50, 75, and 100 micrograms per hour.
Annual global sales of Fentanyl transdermal patches in the European Economic Area were approximately EUR 657 million for the twelve months ending March 2007, according to IMS Health data.
About Actavis Group Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. Based in Iceland, the company has operations in about 40 countries, with more than 11,000 employees. Actavis expects 2007 sales to total EUR1.6bn, with approximately one-third of these sales coming from the United States, the company's single largest market.
Enquiries Actavis Group Hjördís Árnadóttir Director External Communications Tel: (+354) 535 2300 / 840 7476 E-mail: harnadottir@actavis.com
Any statements contained in this news release that refer to Actavis' estimated or anticipated future results or future activities are forward-looking statements which reflect the Company's current analysis of existing trends, information and plans. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially depending on factors such as the availability of resources, the timing and effect of regulatory actions, the success of new products, the strength of competition, the success of research and development issues, unexpected contract breaches or terminations, exposure to product liability and other lawsuits, the effect of currency fluctuations and other factors.
Copyright © Hugin ASA 2007. All rights reserved.
Actavis
http://www.actavis.com
ISIN: IS0000000420
Stock Identifier: ICEX.ACT
 |
Related Industry Topics: |
Financial General | |
| |
This Page Viewed: (Last 7 Days: 40) (Last 30 Days: 100) (Since Published: 11750) |
Events & Exhibitions
|
Site Search
| ENGLISH All Languages |
Companies in the News
ABN Newswire on iPhone/iPad
|
| Download from Apple |
Mobile Video TV
|
||
|
||
